BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
63.42
-2.18 (-3.32%)
Nov 15, 2024, 4:00 PM EST - Market closed
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
The 20 analysts with 12-month price forecasts for BMRN stock have an average target of 94.2, with a low estimate of 65 and a high estimate of 122. The average target predicts an increase of 48.53% from the current stock price of 63.42.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BMRN stock from 21 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 5 | 6 | 5 | 5 |
| Buy | 7 | 7 | 8 | 9 | 10 | 10 |
| Hold | 9 | 8 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 19 | 19 | 21 | 21 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy Initiates $95 | Buy | Initiates | $95 | +49.80% | Nov 15, 2024 |
| Citigroup | Citigroup | Hold Maintains $93 → $81 | Hold | Maintains | $93 → $81 | +27.72% | Oct 30, 2024 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $93 → $84 | Hold | Maintains | $93 → $84 | +32.45% | Oct 30, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $110 → $90 | Buy | Maintains | $110 → $90 | +41.91% | Oct 30, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $110 → $109 | Buy | Maintains | $110 → $109 | +71.87% | Oct 30, 2024 |
Financial Forecast
Revenue This Year
2.87B
from 2.42B
Increased by 18.72%
Revenue Next Year
3.15B
from 2.87B
Increased by 9.64%
EPS This Year
2.09
from 0.87
Increased by 140.78%
EPS Next Year
3.05
from 2.09
Increased by 45.69%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.0B | 3.4B | 3.9B | ||
| Avg | 2.9B | 3.1B | 3.5B | ||
| Low | 2.7B | 2.8B | 2.7B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 23.6% | 19.2% | 23.8% | ||
| Avg | 18.7% | 9.6% | 10.1% | ||
| Low | 9.7% | -2.2% | -13.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.41 | 4.10 | 6.22 | ||
| Avg | 2.09 | 3.05 | 4.06 | ||
| Low | 1.81 | 1.77 | 1.08 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 176.9% | 95.5% | 103.7% | ||
| Avg | 140.8% | 45.7% | 33.0% | ||
| Low | 108.4% | -15.3% | -64.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.